/CYTH
CYTH Stock - Cyclo Therapeutics, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.72+0.00%
+$0.00 (+0.00%) • Mar 26
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+31.8%upside
Target: $0.95
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CYTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.71 – $0.73
TARGET (TP)$0.95
STOP LOSS$0.66
RISK/REWARD1:3.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.57
52W High$1.62
52W Low$0.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $1.08M | $1.38M | $1.59M | $903,376 | $1.01M |
| Gross Profit | $977,947 | $1.24M | $1.43M | $836,978 | $931,705 |
| Gross Margin | 90.9% | 89.9% | 90.2% | 92.7% | 92.5% |
| Operating Income | $-20,050,057 | $-15,611,614 | $-14,268,133 | $-8,960,133 | $-7,390,788 |
| Net Income | $-20,057,302 | $-15,279,890 | $-14,305,177 | $-8,923,073 | $-7,674,278 |
| Net Margin | -1863.4% | -1110.7% | -902.1% | -987.7% | -761.9% |
| EPS | $-1.23 | $-1.81 | $-2.25 | $-5.58 | $-7.09 |
Company Overview
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CYTHBeat Rate
53%
Last 15 quarters
Avg Surprise
-45.0%
EPS vs Estimate
Beats / Misses
8/7
Last 12 quarters
Latest EPS
$-0.26
Q4 2024
EPS Surprise History
Q1 23
-336.0%
$-0.59vs$0.25
Q2 23
-9.5%
$-0.46vs$-0.42
Q3 23
+25.0%
$-0.33vs$-0.44
Q4 23
-7.4%
$-0.29vs$-0.27
Q1 24
-9.5%
$-0.23vs$-0.21
Q2 24
+25.0%
$-0.15vs$-0.20
Q3 24
-50.0%
$-0.21vs$-0.14
Q4 24
-52.9%
$-0.26vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 24, 2025 | $-0.17 | — | — | — |
Q4 2024 | Nov 14, 2024 | $-0.17 | $-0.26 | -52.9% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.14 | $-0.21 | -50.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.20 | $-0.15 | +25.0% | ✓ BEAT |
Q1 2024 | Mar 18, 2024 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.27 | $-0.29 | -7.4% | ✗ MISS |
Q3 2023 | Aug 15, 2023 | $-0.44 | $-0.33 | +25.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.42 | $-0.46 | -9.5% | ✗ MISS |
Q1 2023 | Mar 20, 2023 | $0.25 | $-0.59 | -336.0% | ✗ MISS |
Q4 2022 | Nov 11, 2022 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q3 2022 | Aug 16, 2022 | $-0.49 | $-0.41 | +16.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.48 | $-0.33 | +31.2% | ✓ BEAT |
Q1 2022 | Mar 14, 2022 | $-0.52 | $-0.34 | +34.6% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.67 | $-0.60 | +10.4% | ✓ BEAT |
Q3 2021 | Aug 17, 2021 | $-0.76 | $-0.56 | +26.3% | ✓ BEAT |
Q2 2021 | May 17, 2021 | — | $-0.76 | — | — |
Q1 2021 | Mar 15, 2021 | $-0.33 | $-1.60 | -384.8% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | — | $-0.85 | — | — |
Q3 2020 | Aug 14, 2020 | — | $-1.55 | — | — |
Q2 2020 | May 15, 2020 | — | $-2.17 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CYTH
What is CYTH's current stock price?
Cyclo Therapeutics, Inc. (CYTH) is currently trading at $0.72 per share. The stock has moved +0.00% today.
What is the analyst price target for CYTH?
The average analyst price target for CYTH is $0.95, based on 1 analyst.
What sector is Cyclo Therapeutics, Inc. in?
Cyclo Therapeutics, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is CYTH's market cap?
Cyclo Therapeutics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does CYTH pay dividends?
No, Cyclo Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorELEV
Elevation Oncology, Inc.
$0.36
Mkt Cap: $0.0B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
HEXO
HEXO Corp.
$0.71
Mkt Cap: $0.0B
IVC
Invacare Corporation
$0.66
Mkt Cap: $0.0B
LSB
LakeShore Biopharma Co., Ltd
$0.63
Mkt Cap: $0.0B
MEIP
MEI Pharma, Inc.
$3.07
Mkt Cap: $0.0B
MSPR
MSP Recovery, Inc.
$0.20
Mkt Cap: $0.0B
RNLX
Renalytix Plc
$0.21
Mkt Cap: $0.0B
STRM
Streamline Health Solutions, Inc.
$5.33
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to CYTH for comparison